SF Gate -- When Roche Holding executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals or health care legislation: Did the Genentech team hide the ties of the Roche executives?
